<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus-1 (HIV-1)-Tat, the transactivating gene product of HIV-1, has been shown to interact with different cell types, inducing gene expression, altering their growth and migratory behavior </plain></SENT>
<SENT sid="1" pm="."><plain>In this study we examined whether Tat might affect functions of acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>)-related non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), relevant to the in vivo dissemination </plain></SENT>
<SENT sid="2" pm="."><plain>Our results show that Tat significantly augmented the motility of the two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines (AS283 and PA682PB) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-primary effusion <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HBL</z:e>-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-PEL) </plain></SENT>
<SENT sid="3" pm="."><plain>Mutations in RGD or basic domain of Tat (KGE-MBP and LxI-MBP, respectively) sharply reduced migration compared with <z:mp ids='MP_0002169'>wild type</z:mp>, suggesting that both domains are required for migration </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, a Tat protein mutation outside the active domains (NH(2)-TAT-GST) did not reduce <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell migration </plain></SENT>
<SENT sid="5" pm="."><plain>The treatment of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells with Tat did not influence their <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to matrix proteins or to human vascular endothelial cells, but endothelial cells treated with Tat became more adhesive to <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="6" pm="."><plain>Flow cytometric analysis showed that treatment of endothelial cells with Tat induced the cell surface expression of the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (VCAM-1) and E-selectin and increased the expression of intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1) </plain></SENT>
<SENT sid="7" pm="."><plain>Only antibodies against VCAM-1 on endothelial cells or against the VLA-4 integrin expressed on AS283 cells inhibited the increment of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, indicating the relevance of this pathway in the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells to vascular endothelium </plain></SENT>
<SENT sid="8" pm="."><plain>In our work, we show for the first time that Tat can enhance the migration of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells and their <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to endothelial cells, two processes that may contribute to the malignant behavior of NHL in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> </plain></SENT>
</text></document>